These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 11505177)

  • 21. The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care.
    García-Rodríguez LA; Massó-González EL; Wallander MA; Johansson S
    Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):943-52. PubMed ID: 18425988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Results of a safety initiative for patients on concomitant amiodarone and simvastatin therapy in a Veterans Affairs medical center.
    Karimi S; Hough A; Beckey C; Parra D
    J Manag Care Pharm; 2010 Sep; 16(7):472-81. PubMed ID: 20726676
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipid-lowering agents and the risk of hip fracture in a Medicaid population.
    Ray WA; Daugherty JR; Griffin MR
    Inj Prev; 2002 Dec; 8(4):276-9. PubMed ID: 12460961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Statins and the risk of pneumonia: a population-based, nested case-control study.
    Schlienger RG; Fedson DS; Jick SS; Jick H; Meier CR
    Pharmacotherapy; 2007 Mar; 27(3):325-32. PubMed ID: 17316144
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug-drug interactions through the FDA adverse event reporting system.
    Antonazzo IC; Poluzzi E; Forcesi E; Salvo F; Pariente A; Marchesini G; De Ponti F; Raschi E
    Acta Diabetol; 2020 Jan; 57(1):71-80. PubMed ID: 31203438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of lipid-lowering drugs during 1991-98 in Northern Jutland, Denmark.
    Riahi S; Fonager K; Toft E; Hvilsted-Rasmussen L; Bendsen J; Paaske Johnsen S; Sørensen HT
    Br J Clin Pharmacol; 2001 Sep; 52(3):307-11. PubMed ID: 11560563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients.
    Nichols GA; Koro CE
    Clin Ther; 2007 Aug; 29(8):1761-70. PubMed ID: 17919557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How well tolerated are lipid-lowering drugs?
    Tomlinson B; Chan P; Lan W
    Drugs Aging; 2001; 18(9):665-83. PubMed ID: 11599634
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low myopathy rates associated with statins as monotherapy or combination therapy with interacting drugs in a group model health maintenance organization.
    Shanahan RL; Kerzee JA; Sandhoff BG; Carroll NM; Merenich JA
    Pharmacotherapy; 2005 Mar; 25(3):345-51. PubMed ID: 15843281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Statin use and risk of first-time psoriasis diagnosis.
    Brauchli YB; Jick SS; Meier CR
    J Am Acad Dermatol; 2011 Jul; 65(1):77-83. PubMed ID: 21529997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipid-lowering medication and risk of cancer.
    Olsen JH; Johansen C; Sørensen HT; McLaughlin JK; Mellemkjaer L; Steffensen FH; Fraumeni JF
    J Clin Epidemiol; 1999 Feb; 52(2):167-9. PubMed ID: 10201659
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease].
    Kłosiewicz-Latoszek L; Respondek W; Białobrzeska-Paluszkiewicz J; Grzybowska B; Jakóbisiak-Ostasz B; Stolarska I
    Pol Merkur Lekarski; 2003 Jul; 15(85):42-6. PubMed ID: 14593958
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipid-lowering medication and risk of injury.
    Bovbjerg VE; Siscovick DS; Psaty BM; McCann BS; Koepsell TD; Raghunathan TE; Wagner EH
    J Clin Epidemiol; 1999 Dec; 52(12):1197-200. PubMed ID: 10580782
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lipid-lowering drugs and risk of new-onset diabetes: a cohort study using Japanese healthcare data linked to clinical data for health screening.
    Ooba N; Setoguchi S; Sato T; Kubota K
    BMJ Open; 2017 Jun; 7(6):e015935. PubMed ID: 28667223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of Treatment for Hyperlipidemia with Decreased Total Mortality in Japanese Individuals: the Yamagata (Takahata) Study.
    Daimon M; Oizumi T; Kameda W; Matsui J; Murakami H; Ueno Y; Kubota I; Yamashita H; Kayama T; Kato T
    J Atheroscler Thromb; 2015; 22(10):1030-9. PubMed ID: 26016512
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective prescribing led to overestimation of the benefits of lipid-lowering drugs.
    Glynn RJ; Schneeweiss S; Wang PS; Levin R; Avorn J
    J Clin Epidemiol; 2006 Aug; 59(8):819-28. PubMed ID: 16828675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lipid-lowering drugs, dyslipidemia, and breast cancer risk in a Medicare population.
    Schairer C; Freedman DM; Gadalla SM; Pfeiffer RM
    Breast Cancer Res Treat; 2018 Jun; 169(3):607-614. PubMed ID: 29450675
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
    Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
    Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary prevention with lipid lowering drugs and long term risk of vascular events in older people: population based cohort study.
    Alpérovitch A; Kurth T; Bertrand M; Ancelin ML; Helmer C; Debette S; Tzourio C
    BMJ; 2015 May; 350():h2335. PubMed ID: 25989805
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of Lipid-Lowering Drugs and the Risk of Cataract: A Population-Based Nested Case-Control Study.
    Bezin J; Mansiaux Y; Noize P; Salvo F; Bégaud B; Pariente A
    Clin Pharmacol Ther; 2019 Feb; 105(2):458-465. PubMed ID: 29992538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.